Entelos, Inc. announced that Pfizer has signed an agreement with Entelos to continue research using the Entelos Cardiovascular PhysioLab platform, originally built in collaboration with Pfizer. Financial terms were not disclosed.

"The pharmaceutical and medical communities recognize the importance of treating complex conditions much earlier in the disease process," stated James Karis, president and CEO of Entelos. "We expect to use our new cardiovascular platform to conduct research that goes much deeper into the biology of heart disease to help identify novel approaches and treatments."

Entelos, Inc. is a US-based life sciences company building predictive in silico disease models and using "virtual patients" to revolutionize the way medicines are discovered, developed, and utilized.